Patents

Mode of chromatographic purification of recombinant human erythropoietin
(Spôsob chromatografickej purifikácie rekombinantného ľudského erytropoetínu)
Patent application number: 60-2020, Slovak Patent Office
Patent assignee: Slovak technical University (70%), BMC SAS (30%)
Inventors: POLAKOVIČ, M. – MOLNÁR, T. – ADAMÍKOVÁ, J. – ANTOŠOVÁ, M. – BARTOŠOVÁ, Mária –
ŠKULTÉTY, Ľudovít
https://wbr.indprop.gov.sk/WebRegistre/Patent/Detail/69-2020

BMC SAS is an owner of a series of patents related to the identification of MN/CA IX Gene and protein at the Institute of Virology SAS (continuations-in-part of the parent US patent 5387676, inventors ZÁVADA, Jan – PASTOREKOVÁ, Silvia – PASTOREK, Jaromír), which were registered at US Patent Office.

Soluble form of carbonic anhydrase IX (s-CA IX), assays to detect s-CA IX, CA IX’s coexpression with HER2/neu/c-erbB-2, and CA IX-specific monoclonal antibodies to non-immunodominant epitopes
Patent numbers: US7833728, US7816493, US7846673
Assignee: Institute of Virology
Inventors: PASTOREK, Jaromír – PASTOREKOVÁ, Silvia – ZATOVICOVA, Miriam – Zavada, J. – Ortova Gut, M. – Zavadova, Z.
https://patents.google.com/patent/US7833728B2/en?oq=US7833728
https://patents.google.com/patent/US7816493B2/en?oq=US7816493
https://patents.google.com/patent/US7846673B2/en?oq=US7846673

MN gene and protein
Patent numbers: US7855185, US7851455, US7910549
Assignee: Institute of Virology
Inventors: HARRIS, A.H. – RATCLIFFE, P.J.
https://patents.google.com/patent/US7855185B2/en?oq=US7855185+(B2)
https://patents.google.com/patent/US7851455B2/en?oq=7851455

MN/CA IX/CA9 and Renal Cancer Prognosis
Patent numbers: US7838240
Assignee: Institute of Virology
Inventors: SOYUPAK, B. – ERDOGAN, S.
https://patents.google.com/patent/US7838240B2/en?oq=US7838240

MN/CA IX and EGFR pathway inhibition
Patent numbers: US7820159
Inventors: DORAI, T.
Assignee: Institute of Virology
https://patents.google.com/patent/US7820159B2/en?oq=US7820159

The above-mentioned patents cover the methods of use of the MN/CA IX gene and protein and derived antibodies and/or nucleic acids in cancer diagnostics and therapy. Currently, MN/CA IX antibodies are subject of three non-exclusive licenses to private companies developing anticancer strategies, as described in 2.6.4.2.

List of licences

2017

Title: Non-exclusive License Agreement
Licensee: BioScience Slovakia, s.r.o.
Country: Slovakia
IPR: selected MN/CA IX patents identified in the Annex to Agreement
Contract value: Royalties from sales
Purpose: commercial use of CA IX-specific M75 monoclonal antibody for research and in vitro diagnostics
https://crz.gov.sk/2937225/

Title: Non-exclusive License Agreement
Licensee: WILEX a.g.
Country: Germany
IPR: selected MN/CA IX patents identified in the Annex to Agreement
Contract value: Royalties from sales
Purpose: commercial use of CA IX-specific M75 monoclonal antibody for in vitro diagnostics and patient stratification to mmunotherapy
https://crz.gov.sk/2944845/

Title: Non-exclusive License Agreement
Licensee: MABPRO, s.r.o.
Country: Slovakia
IPR: selected MN/CA IX patents identified in the Annex to Agreement
Contract value: Royalties from sales
Purpose: commercial use of CA IX-specific M75 monoclonal antibody for cancer diagnostics and therapy
https://crz.gov.sk/3049938/

2020

Title: Non-exclusive License Agreement
Licensee: BioLegend, Inc.
Country: California, USA
IPR: internally registered, in-house produced hybridomas
Contract value: Royalties from sales
Purpose: commercialization of monoclonal antibodies specific for Endosialin, a marker of tumor
angiogenesis, for research use
https://crz.gov.sk/4948728

2021

Title: Non-exclusive License Agreement
Licensee: Moredun Research Instiute
Country: Scotland, UK
IPR: internal – live culture of Coxiella burnetii strain RSA439 growing on axenic medium
Contract value: Royalties from sales
Purpose: development of Q fever vaccine
https://crz.gov.sk/zmluva/6026939/